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placed): 0.929(0.712); (undisplaced/displaced): 0.847(0.249); Comorbidities (no/yes):
0.963(0.836); Surgical types (arthroplasty/osteosynthesis): 1.405(0.026); Antiosteo-
porotic treatment (2years/none): 0.512(0.006); (2years/none): 0.529 (0.004).
CONCLUSIONS: The risk of second hip fracture in elderly 8 year follow up period
was the highest in female, in older age-group, in patient after arthroplasty and in
patient without pharmacologic treatment for osteoporosis. The effect of single risk
factors on the risk of subsequent hip fractures should be investigated in the future.
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OBJECTIVES: To perform a systematic review of prospective observational studies
in patients with RA to examine the safety of TNF-I in daily practice, with particular
focus on malignancy, and serious and opportunistic infections. METHODS: Com-
prehensive searches of Medline, Embase, the Cochrane Database of Systematic
Reviews, and ACR, EULAR and BSR conference abstracts were performed according
to a pre-specified protocol that excluded randomised controlled trials. Type and
site of malignancies, as well as serious and opportunistic infections, such as tuber-
culosis, were extracted. Publications that reported incidence rates, standardised
incidence ratios or measures of relative risk, such as incidence rate ratios, odds
ratios or hazard ratios, were selected for random effects meta-analyses. RESULTS:
A total of 2039 papers and 1979 abstracts were identified, of which 48 and 21 re-
spectively met the pre-specified inclusion criteria. The pooled estimate for the
relative risk (RR) of overall malignancy from seven studies was 0.94 (95% CI 0.84,
1.05; I2  0.0%). In contrast, the meta-analysis of serious infections had much
higher heterogeneity, I2 40.9%, RR 1.34 (95% CI 1.06, 1.62). CONCLUSIONS: This
review included data from European, US and Japanese studies with 130,000 pa-
tient years of exposure. Data from such a large number of patients, often with
extended follow-up, overcomes the weaknesses of clinical trial data, specifically
fewer patient numbers and usually shorter exposure times. Observational data has
known weaknesses related to non-randomisation such that statistical techniques
have to be used to overcome differences between the exposed and reference co-
horts. Despite such confounding factors, consideration of the available evidence
leads to the conclusion that there is an increased risk of serious and opportunistic
infections with TNF-I, although no evidence of increased the risk of malignancy.
Meta-analyses of randomised controlled trials have come to different conclusions
regarding both the risk of infections and of malignancy.
Muscular-Skeletal Disorders – Cost Studies
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OBJECTIVES:Objective of the study was the budget impact analysis (BIA) of the use
of abatacept as first biologic line for rheumatoid arthritis (RA) patients in Italy.
METHODS: The BIA was based on a Markov model with 6-months cycles and
3-years time horizon. The target population, formed by RA patients starting a first
biologic treatment, was estimated based on RA prevalence and market share data
for biologic drugs. The sequence including abatacept (ABA) as first line was com-
pared with two more traditional sequences of anti-TNF (IFXinfliximab;
ETNetanercept; ADAadalimumab) and rituximab (RTX). The compared se-
quences were: ABA-IFX-RTX; ETN-IFX-RTX; ADA-IFX-RTX. The switch between
treatments for intolerance, adverse events or lack of efficacy was simulated on the
basis of data from RCTs. The disease progression was classified with the ACR
(American College of Rheumatology) I, II, III and IV functional states. Treatments
efficacy was obtained from published RCTs as average reduction of the Health
Assessment Questionnaire (HAQ) score. The HAQ score was then correlated with
the ACR states. Direct costs were valued in the perspective of the Italian health care
system and classified in purchasing, administration and patients routine manage-
ment (visits, exams, hospital stay and other drugs). RESULTS: Italian target popu-
lation was estimated in about 7000 RA patients. At the end of the third year patients
still on first biologic drug were 5670, 4610, and 4680 in the sequence with ABA, ETN
and ADA. Patients in ACR I or II were 6240, 6160 and 6000 respectively. The annual
cost at the third year was €47.0 million, €48.5 million and €47.8 million for the
sequence with ABA, ETN and ADA respectively. CONCLUSIONS: The use of ABA as
first biologic line treatment for RA showed to provide better control of the disease
along with a positive impact in total costs, when compared with traditional se-
quences based on anti-TNF in Italy.
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OBJECTIVES: Data about the burden of JIA are necessary to allocate health care
resources. METHODS: Records were examined for 6 months retrospectively. Bur-
den of JIA in Russia was gotten by summarizing direct and indirect medical costs of
all patients with JIA. The total number of JIA patients and annualized costs were
calculated based on extrapolation method. RESULTS: Data on 405 patients were
obtained. Group with biologics included 124 patients(30.6%), without biologics –
269(66.4%), data about 9(3%) persons were absent. Among 6 biologics used in Russia
for JIA treatment (Abatacept, Adalimumab, Etanercept, Infliximab, Rituximab and
Tocilizumab), costs of biologics and total costs per patient were the smallest in case
of Etanercept – 5,131 USD and 6,967 USD and the biggest with Rituximab - 19,530
USD and 21,944 USD. One-year direct costs per patient with biologics were 36,065
USD. One-year direct costs per patient without biologics was 3149 USD. Average
one-year indirect costs were the same for patients with and without biologics -
1442 USD. Total number of patients with JIA in 2010 was 18,626 people, only 930(5%)
(data of National Center for Child Health of Russian Academy of Medical Sciences,
Moscow, Russia) received biologics. One-year direct costs of all patients with JIA -
89,491,976 USD; indirect costs - 27,491,976 USD; the burden of JIA -116,754,031 USD.
CONCLUSIONS: In 2010 total number of patients with JIA in Russia was estimates
as 18,626 people; burden of JIA was 116,754,031 USD.
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OBJECTIVES: To estimate the annual cost of etanercept, adalimumab and inflix-
imab per treated patient across adult indications using drug utilization from a US
managed care population.METHODS:MarketScan Commercial Database was used
to identify all adult patients (18-64 years) with 1 claim for etanercept, adali-
mumab, or infliximab between November 1, 2005-June 6, 2009 who were biologic-
naïve or continuing TNF-blocker treatment (i.e., received a TNF-blocker before the
first (index) claim in the study period) and had a diagnosis for rheumatoid arthritis,
psoriasis, psoriatic arthritis, or ankylosing spondylitis. Patients were required to be
continuously enrolled for 6-months pre-index and 1-year following the index
claim. Patients with Crohn’s disease, or ulcerative colitis in the pre-index period
were excluded. Mean monthly dose was calculated for the 3 TNF-blockers for a
12-month period while patients were on therapy. Wholesale acquisition costs and
the Medicare Physician Fee Schedule were applied to the mean monthly dose and
related drug administration to estimate TNF-blocker cost per treated patient.
RESULTS: Overall, 12,065 etanercept, 5,685 adalimumab, and 3,902 infliximab pa-
tients were included. Biologic-naïve patients consisted of 43% of patients. Patient
characteristics were similar across treatment groups with a mean age (SD) of 49 (10)
years and 66% female. The mean annual TNF-blocker cost per treated patient for all
patients was $14,446 for etanercept, $18,000 for adalimumab, and $23,348 for inf-
liximab. In biologic-naïve patients, the TNF-blocker cost per treated patient was
$13,703 for etanercept, $16,932 for adalimumab, and $20,500 for infliximab; in pa-
tients continuing treatment it was $14,901 for etanercept, $19,410 for adalimumab,
and $25,028 for infliximab. CONCLUSIONS: Patients receiving etanercept had the
lowest TNF-blocker cost per treated patient for adult indications when using actual
drug utilization from a US managed care population. TNF-blocker costs per treated
patient on adalimumab and infliximab, respectively are approximately 25% and
62% higher than etanercept.
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OBJECTIVES: To describe annual costs of etanercept, adalimumab and infliximab
per treated patient across adult indications using real-world US drug data.
METHODS: IMS LifeLink™ Health Plan Claims database was used to identify adult
patients (18y) with 1 claim for etanercept, adalimumab or infliximab between
January 1, 2005-March 31, 2009 (first TNF-blocker claim in study period is index
claim); patients who were biologic-naïve or continuing TNF-blocker treatment
were included. Patients had to have 360 days continuous enrollment following
index claim and 180 days prior to index claim (pre-index period). In the pre-index
period, patients were included if they had a diagnosis of rheumatoid arthritis,
psoriasis, psoriatic arthritis, or ankylosing spondylitis, but were excluded if they
had a diagnosis of Crohn’s disease or ulcerative colitis. Patients were followed for
1-year. Mean monthly dose was computed for patients on therapy; wholesale ac-
quisition costs were applied to mean monthly dose and Medicare Physician Fee
Schedule was applied to related drug administrations. Costs from restarting index
TNF-blocker therapy after discontinuation and costs from switching to a different
TNF-blocker were attributed to patients’ index therapy. RESULTS: Overall, 27,704
patients (14,777 etanercept, 6,862 adalimumab, 6,065 infliximab), were identified.
The indication mix was 65% rheumatoid arthritis, 11% psoriasis, 13% psoriatic
arthritis, 5% ankylosing spondylitis, and 6% with multiple indications. The 1-year
mean cost per treated patient for all patients was lowest for etanercept, $14,013,
followed by adalimumab, $17,716, then infliximab, $20,665. For biologic-naïve pa-
tients, mean cost per treated patient was $13,342 for etanercept, $16,718 adali-
mumab, and $18,589 infliximab. For patients continuing biologic therapy, cost per
treated patient was $14,438 for etanercept, $18,816 adalimumab, and $21,846
infliximab. CONCLUSIONS: When comparing TNF-blocker cost per treated patient
across adult indications, etanercept has the lowest cost per treated patient com-
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